UnitedHealth's shares surged 20% over the past month, trading around $389, driven by stronger-than-expected Q1 2026 results with revenue up 2% to $111.7 billion and adjusted EPS of $7.23. Despite Berkshire Hathaway's exit from its UNH stake, the company raised its full-year 2026 adjusted EPS guidance above $18.25, supported by growth at Optum and improved margins. Analysts remain optimistic, with a consensus 'Moderate Buy' rating and an average 12-month price target of $390, reflecting about 20% upside potential. Some risks remain, including Medicaid funding cuts, but overall UnitedHealth is viewed as fundamentally strong in the healthcare sector.
Mizuho increased its price target for UnitedHealth Group from $410 to $440, maintaining an Outperform rating due to signs that medical cost pressures are easing in the managed care sector. The move reflects confidence that the challenging medical los...
Humana's stock has surged 48% over the past month, outperforming peers like UnitedHealth and Cigna, driven by strong Medicare Advantage (MA) growth and favorable regulatory decisions. The company reported Q1 2026 adjusted EPS of $10.31, beating estim...
Berkshire Hathaway, under new leadership, drastically reduced holdings in 16 stocks and trimmed others tied to economic activity, signaling caution about a potential economic slowdown. Despite this, it tripled its investment in Alphabet, valuing the ...
Berkshire Hathaway has fully sold its stake in UnitedHealth Group after buying in mid-2025 when the stock was deeply depressed. The shares rose 45% from $271 to nearly $394 in about nine months, allowing Berkshire to lock in quick profits. This move ...
